ClinicalTrials.gg
RecruitingNCT06846489Updated Jun 3, 2025

Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma

A Phase 2 interventional study of Acalabrutinib and Rituximab in Mantle Cell Lymphoma (MCL), sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-03.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell — 5 open to participants now, 20 under way, 1 of them phase 3. acalabrutinib · Lymphoma, Mantle-Cell.

Planned enrollment
12th of 26
50 · median 49
Started
2025
the only one that year
Phase 2
17 of 26
4 open now
Primary completion
2033-02
later than 19 of 19 live
Registered
25th of 26
by date
Lead sponsor
1 of 26
Sun Yat-sen University

Among the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, this one is the 12th largest by planned enrollment, is the only one that started in 2025, is one of 17 in phase 2, reaches primary completion later than 19 of the 19 other live ones, and was the 25th registered.

Lymphoma, Mantle-Cell

1,223 studies on the registry are indexed under Lymphoma, Mantle-Cell; 156 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

5 of the 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About acalabrutinib

acalabrutinib: first FDA approval 2017 (CALQUENCE), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 93 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing acalabrutinib in Lymphoma, Mantle-Cell, or all of them as a file.
02

Study summary

This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma

Read the detailed description

The purpose of this study is to evaluate the efficacy and safety of Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma

Treatrment:

  1. Acalabrutinib: 100 mg bid po, continue treatment until disease progression, intolerable toxicity, or completion of 24 months of treatment
  2. Rituximab: 375 mg/m2 IV, once weekly during the first cycle, then once monthly for 12 months, followed by once every 2 months, for a maximum of 24 months.

The primary study endpoint is the investigator-assessed complete response (CR) rate at 12 months.

03

Conditions studied

  • Mantle Cell Lymphoma (MCL)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion Criteria:

  1. Age ≥18 years.
  2. confirmed CD20+ mantle cell lymphoma.
  3. No prior anti-lymphoma treatment.
  4. Ann Arbor stage II-IV.
  5. performance status 0-2, no deterioration >2 weeks before baseline or first dose.
  6. Younger subjects (\<65) must meet:

    1. Low to intermediate risk sMIPI (0-5)
    2. Ki67 \< 50%
    3. No TP53 mutation (NGS)
    4. Lesion diameter ≤5 cm
    5. Non-blastoid, polymorphic disease
  7. At least one assessable lesion per Lugano 2014 criteria.
  8. Adequate organ and bone marrow function during screening.
  9. Female subjects must use as per local regulations.
  10. Male subjects must agree to avoid sperm donation during the study and for 12 months post-rituximab.
  11. Willing to undergo all required assessments and procedures, including swallowing capsules/tablets.
  12. Able to understand the study's purpose and risks, and provide signed with authorization for the use of personal health information.

Key exclusion Criteria:

  1. Participants with tumor burden reduction prior to stem cell transplantation.
  2. History of active lymphoma central nervous system (CNS) involvement, , or spinal cord compression.
  3. Any disease evidence deemed by the investigator to be detrimental to the patient's participation or likely to affect protocol adherence (e.g., severe or uncontrolled systemic disease, including uncontrolled hypertension or kidney transplant).
  4. History of progressive multifocal leukoencephalopathy (PML) or current diagnosis of PML.
  5. Received any drug within 30 days (or 5 half-lives, whichever is shorter) prior to the first dose of the investigational drug.
  6. Underwent major surgery within 30 days prior to the first dose of the investigational drug. Note: If the participant has undergone major surgery, they must be fully recovered from any toxicity and/or complications related to the surgery before the first dose.
  7. A history of that could affect protocol adherence or interpretation of results, except for: a. Basal cell carcinoma, squamous cell carcinoma of the skin, cervical carcinoma in situ, or prostate carcinoma in situ treated curatively at any time before the study. b. Other cancers that were treated surgically and/or with radiation, with no disease for ≥3 years without further treatment.
  8. Significant cardiovascular disease, such as symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months before screening, or any Class 3 or 4 heart disease during screening. Note:Participants with well-controlled, asymptomatic atrial fibrillation are allowed.
  9. nausea and vomiting, difficulty swallowing formulations, or malabsorption syndrome; chronic gastrointestinal disease, gastric bypass, or weight-loss surgery (e.g., Roux-en-Y); partial or complete bowel obstruction, or previous major intestinal surgery that may interfere with the absorption, distribution, metabolism, or elimination of the investigational drug.
  10. Received a live-virus vaccine within 28 days prior to the first dose of the investigational drug.
  11. Known infection.
  12. Any active major infection (e.g., bacterial, viral, or fungal, including subjects with positive CMV DNA PCR).
  13. Serologic evidence of active or C infection.
  14. History of stroke or intracranial hemorrhage within 6 months prior to the first dose of the investigational drug.
  15. History of bleeding disorders (e.g., hemophilia, Von Willebrand disease).
  16. Requires or is receiving anticoagulation therapy with warfarin or equivalent vitamin K antagonists.
  17. Requires strong inhibitors or inducers. The use of strong CYP3A inhibitors within 1 week or strong CYP3A inducers within 3 weeks before the first dose of the investigational drug is prohibited.
  18. Pregnancy or breastfeeding.
  19. Participation in another therapeutic clinical trial.
  20. Requires proton pump inhibitor therapy (e.g., omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole).
  21. Currently has a life-threatening disease, medical condition, or organ system dysfunction that, in the investigator's judgment, may compromise the participant's safety or place the study at risk.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Acalabrutinib in combination with Rituximab

    Eligible patients will receive: Acalbrutinib : 100 mg bid po, continue treatment until disease progression, intolerable toxicity, or completion of 24 months of treatment. Rituximab: 375 mg/m² IV, once weekly during the first cycle, then once monthly for 12 months, followed by once every 2 months, for a maximum of 24 months.

    Drug: Acalabrutinib · Drug: Rituximab

Interventions

  • 100 mg bid po, continue treatment until disease progression, intolerable toxicity, or completion of 24 months of treatment.

  • 375 mg/m² IV, once weekly during the first cycle, then once monthly for 12 months, followed by once every 2 months, for a maximum of 24 months

06

What researchers measure

Primary outcomes

  1. Complete Response(CR)

    Defined as the proportion of patients who achieve complete remission

    Time frame: From the start of treatment with the investigational drug until 12 months

Secondary outcomes

  1. Objective response rate(ORR)

    The proportion of patients who achieve complete remission (CR) or partial remission (PR) .

    Time frame: From the start of treatment with the investigational drug until 12 months

  2. Duration of Response(DOR)

    To investigate the preliminary anti-tumor efficacy

    Time frame: The time from the patient's first efficacy assessment achieving CR or PR until disease progression, up to 5 years

  3. Progression-free survival(PFS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: From the date of enrollment until the date of the first documented progression or date of death from any cause, whichever came first, up to 5 years

  4. Overall survival(OS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: From the date of enrollment until the date of death from ant cause, up to 5 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Feb 2033, 93 months after the start.

Of 154 non-industry phase 2 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 108. This study's planned 93 months is above that.

Counting every sponsor, half of 184 studies reached it within 63 months; a quarter within 38 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2025
First posted
Feb 26, 2025
StartActual
Apr 14, 2025
Primary completionEst.
Feb 10, 2033
CompletionEst.
Feb 20, 2033
Last update
Jun 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06846489
Responsible party
Qingqing Cai (MD. PhD., Sun Yat-sen University) — Principal investigator
First posted
Feb 26, 2025
Start date
Apr 14, 2025
Primary completion
Feb 10, 2033 (estimated)
Completion
Feb 20, 2033 (estimated)
Last update
Jun 3, 2025

Study contacts

Qingqing Cai
Contact
caiqq@sysucc.org.cn
02087342823

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Acalabrutinib · Rituximab

Start the discussion